A recent survey of biotechnology firms reported that Trump's planned pharmaceutical tariffs would set back scientific innovation and reduce patients' access to medications.
As Trump Pharmaceutical Tariffs Loom, Drug Industry Pledges Investment in U.S. Manufacturing, Warns of Disruptions
The drug industry is bracing for the Trump administration’s planned tariffs on pharmaceutical products and ingredients, warning of supply chain [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
